News

In partnership with Sanofi, Merrimack completed an extensive Phase II program for MM-121 which was designed to assess the role of ErbB3 in a number of cancer indications

Kala has initiated dosing in its Phase III trial (KPI-121-C-001) to evaluate the safety and efficacy of LE-MPP in managing inflammation and pain associated with cataract surgery. In

Proceeds from the financing will be used to augment Navitor’s proprietary drug discovery platform and accelerate the development of a pipeline of novel drugs that target cellular nutrient

GlycoMimetics is initially exploring the clinical use of the drug candidate to treat acute myeloid leukemia (AML) following preclinical studies of GMI-1271 for blood cancers and other cancers

Out of an abundance of caution, CDC is taking aggressive steps to protect the health of all involved, including providing protective courses of antibiotics for potentially exposed staff.

The ceftolozane/tazobactam is being developed to treat complicated urinary tract and intra-abdominal infections. The submission of NDA is supported by the positive data from two pivotal Phase 3

The decision was taken as the studies showed that orteronel plus prednisone could extend the time patients lived before their cancer progressed but failed to extend overall survival

The patent, entitled Chemically Modified Ligase Cofactors, Donors, and Acceptors, is directed toward the use of modified ligation components to improve fidelity in nucleic acid ligation. The research

The new platform will be based on Akrivis Technologies’ proprietary Z-TECT technology that targets and detects unusually low levels of proteins and molecular targets and Leti’s Lipidot nanovector